背景:据报道,依达拉奉右旋冰片是治疗急性缺血性中风(AIS)的有效神经保护剂。本研究旨在调查依达拉奉右旋冰片对AIS患者功能预后和系统炎症反应的影响。
方法:所有参与者均从2022年1月至2022年12月的AISRNA研究(2019年11月21日注册,NCT04175691[ClinicalTrials.gov])招募。AIS患者根据是否接受依达拉奉右旋冰片(37.5mg/12小时,IV)中风发作后48小时内。通过检测细胞因子(白介素-2[IL-2],IL-4、IL-5、IL-8、IL-6、IL-10、IL-12p70、IL-17、肿瘤坏死因子-α[TNF-α]干扰素-γ[IFN-γ],IFN-α,和IL-1β)在中风发作后14天内。
结果:从AISRNA研究中纳入了85例AIS患者。与未接受此治疗的患者相比,接受依达拉奉右旋冰片治疗的患者的改良Rankin量表评分<2的比例明显更高(70.7%对47.8%;P=0.031)。此外,接受依达拉奉右旋冰片注射的个体显示白细胞介素(IL)-1β的表达水平较低,IL-6和IL-17与IL-4和IL-10在缺血性卒中急性期的表达水平升高(P<0.05)。IL-2、IL-5、IL-8、IL-12p70、肿瘤坏死因子-α、干扰素-γ[IFN-γ],和IFN-α(P>0.05)。
结论:与未进行干预的患者相比,在卒中后90天,依达拉奉右旋冰片治疗具有良好的功能转归;它还抑制了促炎因子的表达,同时增加了抗炎因子的水平。
背景:ClinicalTrials.govNCT04175691。2019年11月21日注册,https://www.
结果:gov/ct2/show/NCT04175691。
BACKGROUND: Edaravone dexborneol has been reported as an effective neuroprotective agent in the treatment of acute ischemic stroke (AIS). This study aimed at investigating the impact of
edaravone dexborneol on functional outcomes and systematic inflammatory response in AIS patient.
METHODS: All participants were recruited from the AISRNA study (registered 21/11/2019, NCT04175691 [ClinicalTrials.gov]) between January 2022 and December 2022. The AIS patients were divided into two groups based on whether they received the treatment of
edaravone dexborneol (37.5 mg/12 hours, IV) within 48 h after stroke onset. Inflammatory response was determined by detecting levels of cytokines (interleukin-2 [IL-2], IL-4, IL-5, IL-8, IL-6, IL-10, IL-12p70, IL-17, tumor necrosis factor-α [TNF-α], interferon-γ [IFN-γ], IFN-α, and IL-1β) within 14 days after stroke onset.
RESULTS: Eighty-five AIS patients were included from the AISRNA study. Patients treated with
edaravone dexborneol showed a significantly higher proportion of modified Rankin Scale score < 2 compared to those who did not receive this treatment (70.7% versus 47.8%; P = 0.031). Furthermore, individuals receiving
edaravone dexborneol injection exhibited lower expression levels of interleukin (IL)-1β, IL-6, and IL-17, along with higher levels of IL-4 and IL-10 expression during the acute phase of ischemic stroke (P < 0.05). These trends were not observed for IL-2, IL-5, IL-8, IL-12p70, tumor necrosis factor-α, interferon-γ [IFN-γ], and IFN-α (P > 0.05).
CONCLUSIONS: Treatment with edaravone dexborneol resulted in a favorable functional outcome at 90 days post-stroke onset when compared to patients without this intervention; it also suppressed proinflammatory factors expression while increasing anti-inflammatory factors levels.
BACKGROUND: ClinicalTrials.gov NCT04175691. Registered November 21, 2019, https://www.
RESULTS: gov/ct2/show/NCT04175691 .